Form 4: Voyager Therapeutics Director Grace Colon Granted 24,000 Stock Options

Voyager Therapeutics, Inc. Director Grace Colon was granted 24,000 stock options with an exercise price of $3.28, vesting based on continued service.

Summary

• Grace Colon, a Director of Voyager Therapeutics, Inc. (VYGR), was granted 24,000 stock options.
• The transaction date for this grant was June 3, 2025.
• Each stock option has an exercise price of $3.28.
• The options are exercisable immediately upon grant and have an expiration date of June 3, 2035.
• The grant was made pursuant to the 2025 Stock Incentive Plan of Voyager Therapeutics, Inc. and is in accordance with its director compensation policy.
• The 24,000 shares of common stock underlying the option will vest upon the earlier of the one-year anniversary of the Vesting Commencement Date (grant date) or the date of the next annual meeting of stockholders, subject to Ms. Colon's continued service as a director.
• Following this transaction, Grace Colon beneficially owns 24,000 derivative securities (stock options) directly.

Sentiment

Score: 6

Explanation: The document reports a routine director compensation event. While it's a positive for aligning interests, it's not a significant operational or financial announcement that would dramatically shift sentiment. It's an expected part of corporate governance.

Positives

• The grant of stock options aligns the director's financial interests with those of the shareholders, incentivizing long-term value creation.
• This is a standard component of director compensation, reflecting a common practice in corporate governance to attract and retain qualified board members.

Negatives

• The exercise of these options in the future could lead to a minor dilution of existing shareholder equity, which is a common characteristic of equity compensation plans.

Future Outlook

The granted stock options are subject to vesting, which will occur upon the earlier of the one-year anniversary of the grant date or the date of the next annual meeting of stockholders, contingent on the director's continued service.

Management Comments

• "This stock option was issued pursuant to the 2025 Stock Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy."
• "The vesting commencement date (the 'Vesting Commencement Date') of the option is the grant date. All of the shares of common stock underlying the option vest upon the earlier of the one-year anniversary of the Vesting Commencement Date or the date of the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service as a director."

Industry Context

The grant of stock options to directors is a common and widely accepted practice across various industries, particularly in the biotechnology sector, as a means of non-cash compensation that ties executive and board performance to shareholder returns.

Comparison to Industry Standards

• The use of stock options as a form of director compensation is a standard practice across publicly traded companies, including those in the biotechnology and pharmaceutical sectors.
• While the specific number of options (24,000) and exercise price ($3.28) are unique to this grant, the mechanism aligns with typical equity compensation structures designed to incentivize long-term commitment and performance.
• Comparable companies in the biotech space frequently utilize similar equity-based incentives for their board members to align interests with company growth and shareholder value.

Corporate Governance

Related Party Transactions

• The grant of 24,000 stock options to Grace Colon, a Director of Voyager Therapeutics, Inc., constitutes a related party transaction as it involves compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: Potential for minor future dilution if options are exercised, but also benefits from increased alignment of the director's interests with long-term shareholder value.
• Director (Grace Colon): Receives equity-based compensation, incentivizing continued service and performance tied to the company's stock price.

Next Steps

• The granted stock options will vest based on the specified conditions (earlier of one-year anniversary or next annual meeting, subject to continued service).
• Upon vesting, the director will have the right to exercise these options to acquire common stock.

Key Dates

Keywords

Voyager Therapeutics, VYGR, Stock Options, Director Compensation, SEC Form 4, Insider Transaction, Equity Compensation, Biotechnology, Corporate Governance